Hormones and Agents Affecting Hormonal Mechanism: Antidiabetic Agents: Others
IBYET1 “Byetta Pen injection” 10ug/dose; 60 dose/pen
適應症：第 II 型糖尿病。
Usual dose:
Diabetes mellitus type II: initial, 5 mcg SC bid within 60 min before the morning and evening meal (approximately 6 hrs or more apart) for 1 mon.; maintenance, may increase to 10 mcg SC bid within 60 min. before the morning and evening meal (approximately 6 hrs or more apart).
Dose adjustment:
Renal impairment: moderate (CrCl 30-50 mL/min), use caution when initiating or increasing a dose from 5-10 mcg. End-stage renal disease receiving dialysis or severe renal impairment (CrCl < 30 mL/min), not recommended.
Adverse effect:
Common: hypoglycemia, diarrhea (13%), indigestion (6%), nausea(44%), vomiting (13%), antibody development (6-9%), dizziness (9%), feeling nervous (9%), headache (9%).
Serious: dehydration, acute hemorrhagic pancreatitis, acute necrotizing pancreatitis, acute pancreatitis, anaphylaxis, hypersensitivity reaction, acute renal failure, angioedema.
健保使用規範：(100/5/1、101/10/1、105/5/1)
1.限用於已接受過最大耐受劑量的metformin及/或sulfonylurea類藥物仍無法理想控制血糖之第二型糖尿病患者。
2.本藥品不得與insulin、DPP-4抑制劑、SGLT-2抑制劑等藥物併用。